{"id":9084,"date":"2025-10-27T21:37:40","date_gmt":"2025-10-27T18:37:40","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=9084"},"modified":"2025-10-27T21:37:40","modified_gmt":"2025-10-27T18:37:40","slug":"supraventricular-tachycardia-svt","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/supraventricular-tachycardia-svt\/","title":{"rendered":"Supraventricular Tachycardia (SVT)\u00a0"},"content":{"rendered":"
Supraventricular Tachycardia (SVT)<\/div>\n
<\/div>\n
Source: JCS Task Force 2025\u2013 EP Session, Dr. Munir Zaqqa (Interventional EP Cardiologist)<\/div>\n
<\/div>\n
Keynotes :<\/div>\n
1.\u2060 \u2060Definition<\/div>\n
\u2022 SVT = abnormal heart rhythm > 100 bpm.<\/span><\/div>\n
\u2022 Originates from the His bundle or above (atrial or AV nodal tissue).<\/span><\/div>\n
<\/div>\n
2.\u2060 \u2060Clinical Presentation<\/div>\n
\u2022 Main symptom: palpitations.<\/span><\/div>\n
\u2022 Other possible symptoms: dyspnea, fatigue, light-headedness, chest discomfort, syncope, or may be asymptomatic.<\/span><\/div>\n
<\/div>\n
3.\u2060 \u2060Initial Assessment Algorithm<\/div>\n
1. Assess patient \u2192 Check vital signs and hemodynamic stability.<\/span><\/div>\n
2. Obtain ECG to confirm tachycardia type.<\/span><\/div>\n
3. If sinus rhythm: search for underlying cause (anxiety, volume depletion, PE, etc.).<\/span><\/div>\n
4. If SVT: determine if patient is stable.<\/span><\/div>\n
<\/div>\n
4.\u2060 \u2060Unstable Patient<\/div>\n
\u2022 Immediate cardioversion (50\u2013200 J synchronized).<\/span><\/div>\n
<\/div>\n
5.\u2060 \u2060Stable Patient \u2013 Stepwise Treatment<\/div>\n
1. Assess mechanism on ECG:<\/span><\/div>\n
A regular narrow-complex tachycardia usually indicates a reentry mechanism, while an irregular pattern suggests atrial fibrillation or other non-reentrant causes (e.g., AF, MAT).<\/div>\n
2. Regular SVT (reentry type):<\/span><\/div>\n
\u2022 Perform Valsalva maneuver (first step).<\/span><\/div>\n
\u2022 If not converted \u2192 Adenosine 6\u201318 mg rapid IV bolus with escalation.<\/span><\/div>\n
\u2022 If still not converted \u2192 AV-nodal blocking agents (beta-blocker or non-DHP CCB).<\/span><\/div>\n
\u2022 If ineffective \u2192 Antiarrhythmic agents (flecainide, propafenone, amiodarone) \u2014 avoid contraindications.<\/span><\/div>\n
\u2022 Cardioversion if pharmacologic treatment fails.<\/span><\/div>\n
3. Irregular tachycardia: manage according to specific protocol (e.g., AF or MAT).<\/span><\/div>\n
<\/div>\n
6.\u2060 \u2060Long-Term Management<\/div>\n
<\/div>\n
a. Patient Education<\/div>\n
\u2022 Avoid caffeine, alcohol, and stress triggers.<\/span><\/div>\n
\u2022 Regular follow-ups for symptom control and drug side effects.<\/span><\/div>\n
\u2022 Monitor heart rhythm and adherence to therapy.<\/span><\/div>\n
\u2022 Watch for recurrence or complications.<\/span><\/div>\n
<\/div>\n
b. Pharmacologic Therapy<\/div>\n
\u2022 \u03b2-blockers (metoprolol 25\u2013100 mg daily; bisoprolol 2.5\u201310 mg daily).<\/span><\/div>\n
\u2022 Calcium-channel blockers (diltiazem 120\u2013360 mg; verapamil 120\u2013240 mg).<\/span><\/div>\n
\u2022 Antiarrhythmics (flecainide, propafenone, amiodarone) \u2014 reserve for refractory cases under specialist supervision.<\/span><\/div>\n
<\/div>\n
c. Electrophysiologic Study & Ablation<\/div>\n
\u2022 Recommended to avoid long-term medications and prevent recurrent hospitalizations.<\/span><\/div>\n
\u2022 Curative success rates > 95 % for AVNRT\/AVRT with low risk of complications.<\/span><\/div>\n
<\/div>\n
7.\u2060 \u2060Key Take-Home Messages<\/div>\n
\u2022 Follow a structured algorithm for SVT recognition and management.<\/span><\/div>\n
\u2022 Early ECG confirmation and stability assessment are crucial.<\/span><\/div>\n
\u2022 Adenosine remains the first-line acute drug for regular narrow complex tachycardia.<\/span><\/div>\n
\u2022 Catheter ablation is the definitive therapy for recurrent SVT.<\/span><\/div>\n","protected":false},"excerpt":{"rendered":"

Supraventricular Tachycardia (SVT) Source: JCS Task Force 2025\u2013 EP Session, Dr. Munir Zaqqa (Interventional EP Cardiologist) Keynotes : 1.\u2060 \u2060Definition \u2022 SVT = abnormal heart rhythm > 100 bpm. \u2022 Originates from the His bundle or above (atrial or AV nodal tissue). 2.\u2060 \u2060Clinical Presentation \u2022 Main symptom: palpitations. \u2022 Other possible symptoms: dyspnea, fatigue, […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-9084","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9084","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=9084"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9084\/revisions"}],"predecessor-version":[{"id":9085,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/9084\/revisions\/9085"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=9084"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=9084"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=9084"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}